Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 2/2022

Inhalt (25 Artikel)

Review – Cancer Research

The role of leucine-rich alpha-2-glycoprotein-1 in proliferation, migration, and invasion of tumors

Meng Lin, Jinmeng Liu, Fengping Zhang, Gaoxiu Qi, Shuqi Tao, Wenyuan Fan, Min Chen, Kang Ding, Fenghua Zhou

Review – Cancer Research

Roles of enhancer RNAs in sex hormone-dependent cancers

Lu Zhang, Xiaoxia Ye, Jieyi Luo, Jiayu Chen, Weirang Zheng, Minhua Wu

Open Access Original Article – Cancer Research

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

Lin Zhou, Xiaomu Wang, Jingya Lu, Xiangning Fu, Yangkai Li

Open Access Original Article – Cancer Research

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Changlong He, Chengcheng Wei, Jun Wen, Shi Chen, Ling Chen, Yue Wu, Yifan Shen, Huili Bai, Yangli Zhang, Xueping Chen, Xiaosong Li

Open Access Original Article – Cancer Research

Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies

Timo O. Odinius, Lars Buschhorn, Celina Wagner, Richard T. Hauch, Veronika Dill, Marta Dechant, Michele C. Buck, Khalid Shoumariyeh, Philipp Moog, Juliana Schwaab, Andreas Reiter, Knut Brockow, Katharina Götze, Florian Bassermann, Ulrike Höckendorf, Caterina Branca, Philipp J. Jost, Stefanie Jilg

Original Article – Cancer Research

Health-related quality of life in children with chronic myeloid leukemia in the chronic phase

Fangyuan Zheng, Xuelin Dou, Liqiang Zhang, Jie Jin, Yanli Zhang, Bingcheng Liu, Li Meng, Xiaofan Zhu, Zesheng Lu, Yueping Jia, Huilan Liu, Hai Lin, Li Zhou, Xielan Zhao, Wei Yang, Hui Sun, Sixuan Qian, Hongxia Ma, Runhui Wu, Leping Zhang, Qian Jiang

Open Access Original Article – Cancer Research

Subtyping non-small cell lung cancer by histology-guided spatial metabolomics

Judith Martha Neumann, Hinrich Freitag, Jasmin Saskia Hartmann, Karsten Niehaus, Michail Galanis, Martin Griesshammer, Udo Kellner, Hanna Bednarz

Original Article – Cancer Research

Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma

Raimonda Kubiliūtė, Kristina Žukauskaitė, Algirdas Žalimas, Albertas Ulys, Rasa Sabaliauskaitė, Arnas Bakavičius, Arūnas Želvys, Feliksas Jankevičius, Sonata Jarmalaitė

Original Article – Cancer Research

Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia

Aurelia Vattai, Nadine Kremer, Sarah Meister, Susanne Beyer, Lucia Keilmann, Anna Hester, Mina Temelkov, Helene Heidegger, Elisa Schmoeckel, Mirjana Kessler, Sven Mahner, Udo Jeschke, Linda Hertlein, Thomas Kolben

Open Access Original Article – Cancer Research

The age-specific differences in histopathological tumor characteristics and TNM classification of breast carcinomas in Quality assured mamma diagnostic (QuaMaDi) program in the state of Schleswig–Holstein in Germany

L.-J. Kramp, M. Mathiak, H.-M. Behrens, F. W. Schäfer, M. van Mackelenbergh, Christoph Röcken

Open Access Original Article – Cancer Research

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study

Qing Chen, Yan Li, Wenjie Zhang, Chen Wang, Shengjie Yang, Qisen Guo

Review – Clinical Oncology

The impact of modern radiotherapy on long-term cardiac sequelae in breast cancer survivor: a focus on deep inspiration breath-hold (DIBH) technique

V. Salvestrini, G. C. Iorio, P. Borghetti, F. De Felice, C. Greco, V. Nardone, A. Fiorentino, F. Gregucci, I. Desideri

Original Article – Clinical Oncology

Multi-institutional survey of thymic carcinoma patients in Hokushin region

Hidetaka Uramoto, Tomoya Takiguchi, Tomonobu Koizumi, Azusa Tanimoto, Ryuji Hayashi, Yozo Nakazawa, Ken-ichi Ito, Mitsutoshi Nakada, Yasuo Hirono, Yoshikazu Nishino, Seiji Yano

Open Access COVID-19 Original Article – Clinical Oncology

Evaluation of the impact of the COVID-19 lockdown on the quality of life of patients monitored for cancer who practice an adapted physical activity: rugby for health

Stéphanie Motton, Kelig Vergriete, Luc Nguyen VanPhi, Eric Lambaudie, Audrey Berthoumieu, Jean Pous, Martine Delannes, Julien Piscione, Caroline Cornou, Benoit Bataille, Diane Saxod, Fabien Pillard

Original Article – Clinical Oncology

Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations

Melanie Erices-Leclercq, Sabine Lubig, Frank Förster, Robert Förster, Stefan Baldus, Christian Rudlowski, Lars Schröder

Original Article – Clinical Oncology

Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia

Lu Yu, Huifang Wang, Robert Peter Gale, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xuelin Dou, Xiaojun Huang, Qian Jiang

Open Access Original Article – Clinical Oncology

Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements

Clemens P. J. G. Wolf, Tobias Rachow, Thomas Ernst, Andreas Hochhaus, Bijan Zomorodbakhsch, Susan Foller, Matthias Rengsberger, Michael Hartmann, Jutta Hübner

Open Access Original Article – Clinical Oncology

Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

Osman Öcal, Kerstin Schütte, Juozas Kupčinskas, Egidijus Morkunas, Gabija Jurkeviciute, Enrico N. de Toni, Najib Ben Khaled, Thomas Berg, Peter Malfertheiner, Heinz Josef Klümpen, Christian Sengel, Bristi Basu, Juan W. Valle, Julia Benckert, Antonio Gasbarrini, Daniel Palmer, Ricarda Seidensticker, Moritz Wildgruber, Bruno Sangro, Maciej Pech, Jens Ricke, Max Seidensticker

Open Access Original Article – Clinical Oncology

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab

Matthew Hummel, Tjerk Bosje, Andrew Shaw, Mark Shiyao Liu, Abhijit Barve, Mudgal Kothekar, Mark A. Socinski, Cornelius F. Waller

Open Access Original Article – Clinical Oncology

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Astrid Bauschke, Annelore Altendorf-Hofmann, Merten Homman, Thomas Manger, Jörg Pertschy, Herry Helfritzsch, Hubert Göbel, Utz Settmacher

Original Article – Clinical Oncology

The effect of surgery plus intensity-modulated radiotherapy on treatment in laryngeal cancer: A clinical retrospective study

Kun Deng, Jingwei Yao, Shuqing Zeng, Meiling Wen, Jialu Huang, Tao Zhu, Shanyan Liu, Jianhong Zuo

Letter to the Editor

Supporting ‘Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer’

Muhammad Shahid Iqbal, Josef Kovarik, Rahul Patil, Charles Kelly

Open Access Correction

Correction to: Long-term small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia after stem cell transplantation

Victoria Ruscher, Sascha Lieber, Jörn‑Sven Kühl, Johannes Schulte, Markus Blankenburg, Tobias Reindl, Pablo Hernáiz Driever

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.